Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > AKI is a common and serious health problem across the world
View:
Post by 2019champs on Nov 21, 2021 11:17am

AKI is a common and serious health problem across the world

Every year it affects over 13M million people, causing nearly 2M deaths. 45-70% of all AKIs are associated with sepsis, with mortality as high as 90%. Sepsis affects nearly 30 million people a year, 9 million of whom eventually die, with one sepsis death occurring every 3.5 seconds. The occurrence of AKI in sepsis is an independent risk factor associated with increased mortality, and it is associated with a poor prognosis in the context of multi-organ dysfunction syndrome. Unfortunately, there is no approved treatment/therapy for this indication. This my friends is why metablok is a big deal.
Comment by SrPlata on Nov 21, 2021 4:22pm
Thanks for your excellent research Champs, I did not realize that 45 to 70% of AKI were caused by Sepsis, We also have plenty more drugs canditates sitting on our bench Like AB569 and BORG, that are waiting to start clinical trials once we get the capital to properly fund them. This will happen once they get the 3rd party review done (could come anyday now). Stock will rise then they will do a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities